rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Alaunos Therapeutics, Inc.

TCRT · Nasdaq

Health CareBiotechnologyAbove a falling average

TCRT stood above a rising 150-day average in 11 of the last 52 weekly readings, and has been out of that trend for the last 29 weeks. It is 21.6% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Above a falling average
Weeks in an uptrend
out for 29
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
30 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 11 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$5,805$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders30+2 on the quarter
New · exited7 · 5
Reported value$205K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.unchanged · filed 7 Aug 202621,353$48K00.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202619,356$44K-3,204−14.2%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202615,497$35K00.0%
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 202614,063$32K00.0%
CITADEL ADVISORS LLCadded · filed 14 Aug 202611,870$27K+1,351+12.8%
OSAIC HOLDINGS, INC.reduced · filed 14 Aug 20261,731$3,907-48−2.7%
Tower Research Capital LLC (TRC)added · filed 11 Aug 20261,621$3,663+38+2.4%
Arax Advisory Partnersnew · filed 10 Aug 20261,216$2,749+1,216
UBS Group AGreduced · filed 13 Aug 2026992$2,242-1,282−56.4%
MORGAN STANLEYadded · filed 13 Aug 2026836$1,889+183+28.0%
30 Jun 2024 – 30 Jun 2026
41729Jun 24Dec 24Jun 25Dec 25Jun 26

Everyone who traded it

Holger Weis Company insiderCEO · last 6 Oct 20261 · 0
Jaime Vieser Company insiderDirector · last 6 Oct 20262 · 1
Michael Allen Jerman Company insiderDirector · last 6 Oct 20260 · 0
Robert W. Postma Company insiderDirector · last 6 Oct 20262 · 0
Ferdinand Groenewald Company insiderVice President of Finance · last 18 Aug 20250 · 0
Dale Curtis Hogue, Jr. Company insiderDirector, Officer · last 29 Mar 20250 · 0
Melinda Lackey Company insiderLegal & Administration · last 29 Mar 20250 · 0
Robert Hofmeister Company insiderDirector · last 6 Jun 20240 · 0
Kevin S. Boyle, Sr. Company insiderChief Executive Officer · last 1 Sep 20232 · 1
James Huang Company insiderDirector · last 6 Jun 20231 · 0
Mary Thistle Company insiderDirector · last 6 Jun 20230 · 0
Abhishek K. Srivastava Company insiderOfficer · last 15 Mar 20230 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-196%
Share count trendFY 2025 · to 31 Mar 20261.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$1.4M
Free cash flowFY 2025 · to 31 Dec 2025−$3.0M

Analyst forecasts

No analyst forecasts yet.